What is the fair value of AMGN?

Based on inv-AI’s institutional-grade analysis, the 12-month fair value estimate for Amgen Inc. (AMGN) is $344 (range: $292–$396). Confidence level: MEDIUM.

Is AMGN overvalued or undervalued?

Amgen Inc. (AMGN) is rated Fairly Priced (Mid) by inv-AI. The current price is $348.43 versus a mid fair value of $344, implying -1.3% upside.

What is the AMGN price target for 2026?

inv-AI’s 2026 fair value range for Amgen Inc. (AMGN) is $292 (bear) to $396 (bull), with a base case of $344.

Amgen Inc. (AMGN) Valuation

Rating: Fairly Priced (Mid)

12-Month Fair Value: $292 – $344 – $396

Confidence: MEDIUM

Amgen navigating Prolia/XGEVA biosimilar erosion and IRA-driven Enbrel collapse. Growth portfolio performing: Repatha +36%, EVENITY +34%. MariTide Phase 3 (obesity, monthly dosing, 20% weight loss) is transformative optionality in $100B+ market. Iran war is second-order. FV $344 nearly at current price. HOLD.

View full report | All intelligence | Home